Paradigm Shifts in Lipid Lowering

Manesh Patel, MD, discusses the pathophysiology of the relationship between hypercholesterolemia and cardiovascular disease.

Expert panel of cardiologists provide their perspective on the specific population that may be at a risk of developing hyperlipidemia.

Norman Lepor, MD, FACC, FAHA, FSCAI, shares how he would identify and monitor patient populations at high risk for CV morbidity and mortality.

Linda Hemphill, MD, shares her views on how familial hypercholesterolemia impacts the assessment of high-risk patients.

Dean Karalis, MD, provides his perspective on intensive LDL lowering in patients with risk for high cholesterol and related disorders.

Manesh Patel, MD, briefly addresses the mechanism of action of inclisiran as an adjunct therapy for lipid lowering in patients with high cholesterol.

Cardiologists briefly review the outcomes data and practical implications of novel treatment options for hyperlipidemia.

Panel of experts discuss the use and safety profile of purified icosapent ethyl compound (EPA) in prevention of CV risk.

Experts review in detail the emerging use of inclisiran as an adjunct therapy for lipid lowering in patients with high cholesterol.

Norman Lepor, MD, FACC, FAHA, FSCAI, reviews the efficacy of inclisiran in terms of LDL reduction based on the pooled analysis of the phase 3 ORION trials.

Key opinion leaders in cardiology share their perspectives on using inclisiran post FDA approval within the current treatment landscape based on guidelines.

Norman Lepor, MD, FACC, FAHA, FSCAI, challenges the use of ezetimibe before a PCSK9 inhibitor in a population with no acute coronary syndrome.

Expert cardiologists express support for the uptake in the use of inclisiran once approved based on the cost-effectiveness.

Dean Karalis, MD, provides expertise on the appropriate use of statins based on primary and secondary prevention.

Role of dietary and lifestyle modifications as part of lipid management.

Bempedoic acid monotherapy and its combination with ezetimibe for lipid lowering in patients intolerant to statins.

Importance of shared decision making and value-based care when making treatment decisions for cardiovascular patients.

Final thoughts from expert KOLs regarding treatment decisions and how they relate to patient accessibility when manage dyslipidemia.